


Journal Pre-proof

Standardization of reporting obstructive airway disease in children: A national Delphi process

Carmen CM. de Jong, MD, PhD, Cristina Ardura-Garcia, MD, PhD, Eva SL. Pedersen, PhD, Maria Christina Mallet, MBChB, Dominik Mueller-Suter, MD, Anja Jochmann, MD, PhD, Florian Singer, MD, PhD, Carmen Annemarie Casaulta, MD, Nicolas Regamey, MD, Alexander Moeller, MD, Myrofora Goutaki, MD, PhD, Claudia E. Kuehni, MD, Msc



PII: S2213-2198(22)00936-9

DOI: <https://doi.org/10.1016/j.jaip.2022.08.050>

Reference: JAIP 4406

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 26 February 2022

Revised Date: 17 July 2022

Accepted Date: 30 August 2022

Please cite this article as: de Jong CC, Ardura-Garcia C, Pedersen ES, Mallet MC, Mueller-Suter D, Jochmann A, Singer F, Casaulta CA, Regamey N, Moeller A, Goutaki M, Kuehni CE, Standardization of reporting obstructive airway disease in children: A national Delphi process, *The Journal of Allergy and Clinical Immunology: In Practice* (2022), doi: <https://doi.org/10.1016/j.jaip.2022.08.050>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

Standardization of reporting obstructive airway disease in children:

A national Delphi process

Carmen CM de Jong (carmen.dejong@insel.ch), MD, PhD^{1,2}; Cristina Ardura-Garcia (cristina.ardura@ispm.unibe.ch), MD, PhD¹; Eva SL Pedersen (eva.pedersen@ispm.unibe.ch), PhD¹; Maria Christina Mallet (maria.mallet@ispm.unibe.ch), MBChB^{1,3}; Dominik Mueller-Suter (dominik.mueller-suter@ksa.ch), MD⁴; Anja Jochmann (anja.jochmann@ukbb.ch), MD, PhD⁵; Florian Singer (florian.singer@uzh.ch), MD, PhD⁶; Carmen Annemarie Casaulta (carmenannemarie.casaulta@ksgr.ch), MD⁷; Nicolas Regamey (nicolas.regamey@luks.ch), MD⁸; Alexander Moeller (alexander.moeller@kispi.uzh.ch), MD⁶; Myrofora Goutaki (myrofora.goutaki@ispm.unibe.ch), MD, PhD^{1,2}; Claudia E Kuehni (claudia.kuehni@ispm.unibe.ch), MD, MSc^{1,2}

Corresponding author: Prof. Claudia E. Kuehni, Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland, +41 31 631 35 07, Claudia.kuehni@ispm.unibe.ch

Affiliations

1. Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland

2. Division of Respiratory Medicine, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland

3. Graduate School for Health Sciences, University of Bern, Switzerland

4. Department of Paediatrics, Kantonsspital Aarau, Switzerland

5. Department of Paediatric Pulmonology, University Children's Hospital Basel, Switzerland

6. Division of Paediatric Pulmonology, University Children's Hospital Zurich, Switzerland

7. Department of Pediatrics, Children's Hospital of Graubunden, Chur, Switzerland

8. Division of Paediatric Pulmonology, Children's Hospital, Cantonal Hospital Lucerne,

Switzerland

Disclosure statement

de Jong CCM, Ardura-Garcia C, Pedersen ESL, Mallet MC, Mueller-Suter D, Jochmann A, Casaulta CA, Regamey N, Moeller A, Goutaki M and Kuehni CE have nothing to disclose. F. Singer reports personal fees from Novartis, personal fees from Vertex, grants from Swiss Cystic Fibrosis Society, grants from Lungenliga Bern (Bern lung foundation), outside the submitted work.

Funding

This study was funded by the Swiss National Science Foundation (32003B_162820/1) and supported by the Research Fund of the Swiss Lung Association, Bern (2019-03_641670). Further funding to develop the Swiss Pediatric Airway Cohort (SPAC) came from the Lung League St. Gallen, Switzerland.

Word count:

Abstract: 248 words

Manuscript: 3160 words

47 **Abstract**

48 **Background**

49 Pediatric pulmonologists report asthma and obstructive bronchitis in medical records in a
50 variety of ways and there is no consensus for standardized reporting.

51 **Objective**

52 We investigated which diagnostic labels and features pediatric pulmonologists use to
53 describe obstructive airway disease in children and aimed to reach consensus for
54 standardized reporting.

55 **Methods**

56 We obtained electronic health records from 562 children participating in the Swiss Pediatric
57 Airway Cohort (SPAC) from 2017 to 2018. We reviewed the diagnosis section of the letters
58 written by pediatric pulmonologists to referring physicians and extracted the terms used to
59 describe the diagnosis. We grouped these terms into diagnostic labels (e.g., asthma) and
60 features (e.g., triggers) using qualitative thematic framework analysis. We also assessed
61 how frequently the different terms were used. Results were fed into a modified Delphi
62 process to reach consensus on standardized reporting.

63 **Results**

64 Pediatric pulmonologists used 123 different terms to describe the diagnosis, which we
65 grouped into 6 diagnostic labels and 17 features. Consensus from the Delphi process
66 resulted in the following recommendations: (i) to use the diagnostic label "asthma" for
67 children older than 5 years and "obstructive bronchitis" or "suspected asthma" for children
68 younger than 5 years; (ii) to accompany the diagnosis with relevant features: diagnostic
69 certainty, triggers, symptom control, risk of exacerbation, atopy, treatment adherence, and
70 symptom perception.

Conclusion

We found great heterogeneity in the reporting of obstructive airway disease among pediatric pulmonologists. The proposed standardized reporting will simplify communication among physicians and improve quality of research based on electronic health records.

Highlights box

1 What is already known about this topic?

Pediatric pulmonologists use a myriad terms to report asthma and obstructive bronchitis in medical records due to the lack of consensus on standardized reporting. (24/35 words)

2 What does this article add to our knowledge?

This is the first study that analyzed the terms used by pediatric pulmonologists to report diagnosis of obstructive airway disease in medical records and proposed standardized reporting based on consensus among specialists (32/35 words)

3 How does this study impact current management guidelines?

We recommend standardized reporting for children's obstructive airway disease that includes diagnostic labels and features that are relevant for treatment and follow-up. (22/35 words)

Key words: asthma, diagnosis, children, clinical practice, diagnostic labels, standardization, standardized reporting, reporting

- 82 List of abbreviations
- 83 API - Asthma predictive index
- 84 FeNO - Fractional exhaled nitric oxide
- 85 FEV1 - Forced expiratory volume in the first second
- 86 GINA – Global initiative for asthma
- 87 ICD – international classification of diseases
- 88 IQR – interquartile range
- 89 KEB - Cantonal Ethics Committee Bern (Kantonale Ethikkommission Bern)
- 90 PARC - Predicting asthma risk in children
- 91 REDCap – Research Electronic Data Capture
- 92 SPAC – Swiss Pediatric Airway Cohort
- 93
- 94

95 Introduction

96 Obstructive airway disease in children (e.g., obstructive bronchitis, asthma) is
97 difficult to diagnose because symptoms are unspecific, vary over time, and are difficult for
98 parents to describe [1-3]. Moreover, several tests are used to support the diagnosis, but
99 there is no standalone diagnostic test [1, 2]. In infants and pre-school children diagnosis is
100 especially difficult, as they cannot perform standard lung function tests, and symptoms of
101 viral infections such as bronchiolitis can be similar [4]. Obstructive airway disease is also a
102 heterogeneous entity including many subtypes (phenotypes), meaning that children with
103 obstructive airway disease can have different clinical presentations and underlying etiology
104 [5-8]. Therefore, the diagnosis is not uniform nor certain. Uncertainty is also reflected in
105 physician's phrasing when they describe the diagnosis in medical records. Some physicians
106 only report a single diagnosis of asthma, while many complement it by adding features such
107 as severity, triggers or symptom control. These inconsistencies can lead to problems when
108 patients are treated by different doctors, and when medical records are used in research.
109 Although medical records may be less vulnerable to recall bias and more objective than
110 patient reported information, the lack of standardized reporting complicates the use of
111 diagnoses from medical records, which in turn affects research based on these information
112 sources. For instance, these inconsistencies complicate ensuring accurate
113 inclusion/exclusion criteria for observational or interventional studies. A more standardized
114 reporting of obstructive airway disease would thus facilitate clinical research and
115 communication between physicians, for instance when a patient switches doctor or
116 hospital.

117 A measure to overcome heterogeneous reporting of diagnosis in medical records is
118 the international classification of diseases (ICD). However, ICD-10 only differentiates asthma

into allergic, non-allergic, mixed, and not further specified [9]. This does not reflect the current scientific understanding. Previous studies aiming to standardize reporting for obstructive airway disease assessed which features were reported by guidelines and studies, but not the terms used in clinical practice [10-13]. The few exceptions were done in an adult primary care setting [14, 15]. We therefore lack real-world evidence on the diagnostic labels and features that pediatric pulmonologists use to describe obstructive airway disease in medical records.

In this study, we (1) investigated the diagnostic labels and descriptive features used by pediatric pulmonologists to describe obstructive airway disease in children and, based on this, (2) conducted a Delphi process with the goal to recommend a standard way of reporting children's obstructive airway disease in medical records.

Methods

Study population

We conducted this study using medical records from children participating in the Swiss Paediatric Airway Cohort (SPAC). SPAC is an observational study of children (0-17 years) referred to pediatric pulmonary outpatient clinics in Switzerland for respiratory symptoms such as wheeze, cough, dyspnea, or exercise-related respiratory symptoms. The SPAC study protocol has been published elsewhere [16]. Importantly, as SPAC is observational and embedded in routine care, it does not standardize reporting of information in medical records, nor diagnostic investigations or treatments. For SPAC, original data is extracted from medical records and patient-reported information is extracted from questionnaires. The questionnaire data was used only to describe the characteristics of the study population (i.e. reported symptoms and medication use in the past 12 months). For the main analysis, we only used data derived from medical records.

Study design

From medical records, we collected the hospital letters, which were sent by pediatric pulmonologists to the referring physicians (pediatricians or general practitioners) after a child's consultation in the outpatient clinics. We analyzed the descriptions of the diagnosis from the diagnosis section of these letters. We included one letter from each child (aged 0-17 years) who visited a participating SPAC outpatient clinic between July 2017 and November 2018 and who was diagnosed with an obstructive airway disease (Figure 1). If the child had multiple letters, we selected the letter from the first visit after which the parents gave informed consent. We read all diagnosis sections of these letters and included the child in the study if the diagnosis section of the hospital letter contained the terms "asthma,"

“wheeze,” and/or “obstructive bronchitis”. We then went through the remaining records again, to make sure that we had not missed children with obstructive airway disease labelled differently (e.g. as bronchial hyperreactivity or hyperresponsiveness). The inclusion of the child was independent of the pediatric pulmonologist who wrote the letter. The seven centers participating in SPAC represent all larger pediatric pulmonary outpatient clinics from German-speaking regions of Switzerland. All participating centers are either secondary or tertiary board qualified training centers in Pediatric Pulmonology. There were 1-5 board qualified pediatric pulmonologists working in each center.

Study procedures

The pediatric pulmonologists wrote the hospital letter or supervised the writing by junior physicians. The letter always starts with listing the diagnoses and then summarizes history, findings, interpretation, and suggested management. We entered all relevant information from the letters into an online REDCap database.

Qualitative analysis

We imported the text describing diagnoses into NVivo 12 to aid in the organization and classification of the text. We identified diagnostic labels and features used in the hospital letters to describe obstructive airway disease using thematic framework analysis (Figure 2). A physician (CdJ) coded the words used to describe obstructive airway disease in the diagnosis list using open-end coding. Next, we grouped the codes into themes, from now on called diagnostic labels, if the code was a term for the disease such as “asthma”, or features if the code described the disease such as symptoms and triggers. Through this analysis, a list of diagnostic labels and features was produced (Table E1).

180

181 **Quantitative analysis**

182 We assessed how frequently each diagnostic label and feature was mentioned in the
183 diagnosis section of the 562 hospital letters and stratified the results by age group and
184 clinic. Because of children's inability to perform standard lung function tests under age 5
185 and increased self-management of symptoms during teenage years, we defined 3 age
186 groups: 0-4, 5-9, and 10-17 years. We used descriptive analysis in STATA Version 15 and
187 displayed proportions in histograms. Based on the frequency of use, we wrote a
188 recommendation for each diagnostic label and feature. For example, "In standardized
189 reports of obstructive airway disease in children, triggers should be stated". These
190 recommendations were then used to start the Delphi process.

191

192 **Delphi process**

193 To propose a standardized way of reporting obstructive airway disease based on a
194 consensus, we followed a modified Delphi process with several rounds of questionnaires
195 [17]. For the Delphi process we invited one representative from each clinic who was either
196 the head pulmonologist or was appointed by the head to be the center's representative for
197 the study, so they all had a strong interest in the topic. The pediatric pulmonologists
198 participating in the Delphi process are closely collaborating with colleagues from other
199 European countries, in particular those organized with the ERS. They join international
200 conferences, are members of ERS taskforces and scientific groups, and are trained
201 according to the international guidelines including the HERMES exam of the European
202 Respiratory Society, with the resources required for their training on site. The first Delphi
203 questionnaire consisted of the list of recommendations for each diagnostic label and feature
204 obtained from our qualitative analysis. We also included information on frequency of use of

205 these terms from our quantitative analysis. Pediatric pulmonologists could anonymously
206 agree or disagree with each recommendation and they could write alternative
207 recommendations if they chose. For each questionnaire, we analyzed the level of agreement
208 and developed the next Delphi questionnaire with revised recommendations. After three
209 rounds, we reached consensus with at least 70% agreement.

210

211 **Ethics statement**

212 The SPAC study has been approved by the Cantonal ethics committee of Bern (KEB
213 2016-02176) in Switzerland. All participating parents and adolescents 14 years or older gave
214 informed written consent.

215

216

217 **Results**

218 **Characteristics of the study population**

219 We included hospital letters from 562 patients (65% male, median age 8 years,
220 interquartile range [IQR] 5-11) (Figure 1 and Table I). Forty percent of the letters came from
221 a first visit of a child in the hospital, 60% from a follow-up visit. Respiratory symptoms
222 included wheeze, exercise-induced problems, dyspnea, night cough, and prolonged cough
223 (>4 weeks in a row) (Table I). Overall, 509 (91%) children had used asthma inhalers including
224 390 (69%) with inhaled corticosteroids.

225

226 **Spectrum and grouping of terms used to describe obstructive airway disease**

227 We identified 123 codes used to describe obstructive airway disease in the diagnosis
228 section of these 562 letters. We grouped these codes into 6 diagnostic labels and 17
229 features (Table E1).

230 *The 6 diagnostic labels* used were (1) bronchial asthma (used 446 times), (2) asthma
231 (used 54 times), (3) small airways disease (used 2 times), (4) episodic viral wheeze (used 36
232 times), (5) multiple trigger wheeze (used 11 times), and (6) obstructive bronchitis (used 83
233 times). Often multiple labels were reported and the use of labels varied by age. Obstructive
234 bronchitis, episodic viral wheeze or multiple trigger wheeze were reported in 88% of the
235 diagnosis of children aged 0-4 years.

236 *The 17 features* used in the diagnosis section, in addition to the diagnosis itself,
237 were: (1) certainty of diagnosis (e.g., "suspected" and "probably"); (2) age related
238 phenotype (e.g., "pediatric," "infant," and "toddler"); (3) symptoms (such as "cough" and
239 "dyspnea"); (4) symptom perception; (5) pattern of symptoms over time (e.g., "recurrent,"
240 "chronic," and "episodic"); (6) seasonal or perennial; (7) triggers (e.g., "allergic," "infection,"

and "exercise"); (8) related measures of disease severity, including terms describing the severity directly, such as "mild," "severe," and "difficult to treat," along with terms describing the frequency and severity of exacerbations, stability, and the effects on daily life; (9) lung function, which included the terms "obstructive," "partially reversible," and forced expiratory volume in 1 second (FEV1) values; (10) airway inflammation (e.g., fractional exhaled nitric oxide (FeNO) values); (11) airway hyperresponsiveness (e.g., "mild," "moderate," or "severe hyperresponsiveness" in "methacholine," "mannitol," or "exercise challenge test"); (12) atopy, including terms describing allergens children are sensitized to and the clinical relevance of the sensitizations; (13) therapy (e.g., medications); (14) symptom control (e.g., "uncontrolled" and "well controlled"); (15) therapy response (e.g., "poor" or "good response to treatment"); (16) compliance (e.g., "malcompliance" and "medication frequently forgotten"); (17) risk of future asthma (e.g., asthma predictive index [API] and predicting asthma risk in children [PARC] scores) [18, 19]. Several terms reported in the diagnosis list did not fit into any of these features and were only used once ("type II", "atypical", "known", "residual", and "since").

Frequency of used features to describe a diagnosis of obstructive airway disease

The most frequently reported features were atopy (431, 77%) and triggers (468, 81%) (Figure 3, Table E1). Patterns of symptoms over time (mainly "recurrence"), symptom control, certainty of diagnosis (mainly "suspected"), and related measures of disease severity (mainly "hospitalizations") were mentioned in 97-139 (17-25%) of the letters. Test results other than atopy, such as lung function and airway hyperresponsiveness, were mentioned in 11-52 (2-9%) of the letters. Compliance, symptom perception, therapy response and asthma prediction scores were rarely reported (3-10 times, 1-2%).

The frequency, in which the 17 features were mentioned in hospital letters, varied by patients age (Figure 3). Certainty of diagnosis, age related phenotypes, patterns of symptoms over time, measures of disease severity, and asthma prediction scores were mostly reported for preschool children, while triggers, allergy and other test results, symptom control, and symptom perception were mainly mentioned for children aged 5-17 years. Compliance was exclusively reported in children aged 10-17 years.

We found great heterogeneity between clinics in the reporting of diagnoses and related features. Most frequently mentioned across all clinics were certainty of diagnosis, patterns of symptoms over time, triggers, measures of disease severity, atopy, and symptom control (Figure 4).

Delphi process: Recommended standardized reporting for obstructive airway disease

We reached 71-100% agreement for each of the standardized reporting recommendations for obstructive airway disease after 3 rounds of the Delphi questionnaires (Table E2). Our final recommendations include the diagnosis and 7 features: certainty of diagnosis, triggers, symptom control, risk of exacerbation, atopy, treatment adherence, and symptom perception (Table II). Table III shows examples of standardized reporting of obstructive airway disease for two children.

In the first round, we reached agreement about reporting in the diagnosis list certainty of diagnosis (100%), triggers (100%), atopy and its clinical relevance (100%), symptom control (100%), and treatment adherence (71%). We also agreed to leave out information about reported symptoms (71%), the date of diagnosis (100%), frequency of episodes (71%), stability (100%), limitations during sports and daily activities (71%), therapy (86%), and prediction scores (100%) in the diagnosis section of the letter.

In the second round, we reached agreement to report the diagnostic label asthma (e.g., leaving out the label “bronchial”) in children aged 5 years or older (81%). We agreed to include the severity as “severe” or “difficult to treat asthma” if the Global Initiative for Asthma (GINA) guideline definitions are met (86%), but to drop “mild” or “moderate” severity as there are no guideline definitions for these severities (100%). We agreed to add risk of exacerbation in the diagnosis list as an additional marker of severity by including the number of severe exacerbations in the last 12 months, and month and year of the last severe exacerbation (100%). We agreed as well to include differential diagnoses if the diagnosis was only suspected (86%), poor symptom perception (100%), and airway hyperresponsiveness as a measure of the certainty of diagnosis (86%). We decided to drop symptom persistence and seasonality since this information is also captured by triggers (100%), and to drop treatment step according to GINA guidelines (86%).

In the third round, we agreed to distinguish two diagnostic labels for children under age 5 years (A) recurrent obstructive bronchitis and (B) suspected asthma (which cannot be confirmed because the child is too young to measure spirometry and FeNO (100%). We agreed to use the label obstructive bronchitis if attacks are only triggered by infections and to use the label suspected asthma if any other trigger is present (exercise outside of an infection period or an allergic trigger). We also agreed to list results of relevant diagnostic tests in the diagnosis list to display the level of certainty of the diagnosis (100%). For example, “asthma confirmed by a methacholine challenge test in 09/2020.”

Discussion

This study is the first to propose standardized reporting recommendations for diagnostic labels of obstructive airway disease in children. The recommendations are based on an analysis of the diagnosis section from 562 hospital letters sent in 2017 and 2018 from pediatric pulmonology outpatient clinics of 7 Swiss hospitals to the referring physician. This evidence, which reflects current practice, was used to guide a Delphi consensus process among pediatric pulmonologists in the German-speaking part of Switzerland.

Comparison with other studies

We found four other studies that proposed standardized ways physicians should use to describe a diagnosis of asthma. All are from primary care and relate to adult patients and all based their recommendations either on features mentioned in national registries, in guidelines, or in the literature. A Swiss study systematically reviewed scientific articles and clinical guidelines to identify evidence-based indicators (i.e., features) that could be used to monitor adult chronic conditions for primary care [10]. They found 21 features for asthma: diagnostic tests and results (e.g., spirometry, bronchial provocation test), symptoms, activity limitations, symptom control, smoking (e.g., habit and cessation advice), therapy, triggers, exacerbations, and adherence. The list is comparable to ours, except for smoking, which is less relevant for childhood asthma.

Minard et al. performed a literature review to identify studies that propose a standardized asthma data set for clinical research. [20] As they did not identify any study, they asked a team of 50 different health care administrators, health care workers, and information management/technology experts to select relevant features of asthma in adults. They selected: certainty of diagnosis, diagnostic test results (spirometry, bronchial

provocation, and allergy test), smoking, occupation, triggers, asthma control, symptoms, activity limitations, exacerbations, measures to prevent exacerbations (environmental, smoking cessation, immunization), adherence, and therapy. We have a similar list but we kept fewer features in our final recommendation because the participating pediatric pulmonologists wanted to keep the diagnosis list as concise as possible to improve feasibility of its use in everyday clinical care.

Two studies on asthma in adults did also use a Delphi process to reach consensus for standardized reporting, as it allows stakeholders to shape and support the recommendations, especially when those recommendations are based on current practice. A study from the UK obtained consensus among an international team of 27 experts on features to include in an international severe asthma registry. They selected features based on existing national severe asthma registries and reached consensus after 3 Delphi rounds and 2 meetings [13]. They selected: patient details like height and weight, occupation, medical history including smoking, comorbidity, blood/sputum, allergy, lung function and other test results, symptom control, medication, GINA treatment step, adherence, and management plan. In our study, the pediatric pulmonologists agreed after 3 Delphi rounds so an extra meeting was not necessary. A Dutch study aimed to achieve consensus for standardized reporting of asthma in medical records for general practice. They started with a list of 65 features used in the Dutch College of General Practitioners guidelines to describe a diagnosis of asthma. After 3 Delphi rounds and one meeting to resolve the final disagreements, they concluded that a modified Delphi procedure is an appropriate method to reach agreement on standardized reporting for medical records. They stated that a starting point, such as a set of existing guidelines, is essential for the success of the process [12]. Unfortunately, they did not publish a list of the selected features. We also believe that

we reached consensus relatively easily (after only 3 rounds) because we started the discussion by presenting results from the analysis of the terms pediatric pulmonologists had used over the previous 2 years.

Choosing diagnostic labels for obstructive airway disease in children has been a matter of debate. Although many studies attempted to distinguish between subgroups of patients and to define phenotypes [21-23] others do not support the distinction of asthma phenotypes for clinical care because phenotypes may change over time within a child, and there is no general agreement on how to define phenotypes prospectively [23-25]. Instead, studies suggest to report a simple diagnostic label (e.g., asthma), plus relevant features or traits, which ideally are treatable [5-8]. The distinction in diagnostic label for children under and over age 5 years is a consequence of the uncertainty of diagnosis in young children because they cannot perform most diagnostic tests yet [21-25]. For children younger than age 5, we distinguished between “obstructive bronchitis” if the trigger is only infectious and “asthma” if children also report triggers other than infections. Many preschool children have only few episodes of wheeze triggered by respiratory infections. Preschoolers reporting wheeze triggered apart from infections have a higher likelihood to remain symptomatic later in life. As these children cannot perform standard objective tests, information about triggers of episodes of bronchial obstruction is important for the prognosis and follow-up care [21-25]. Adding explanatory features is important because a simple diagnostic label (e.g., asthma) does not cover the heterogeneity of the disease [5-8, 24, 25]. Also, our participants agreed that, in addition to a simple diagnostic label, it is important to report features relevant for treatment and follow-up.

Strengths and limitations

Our study is the first to propose standardized reporting of diagnosis in children with obstructive airway disease. We expect that our recommendations have a good chance to be implemented in clinics because they are based on empirical evidence from current clinical practice and have been agreed upon in a Delphi process by a large number of leading pediatric pulmonologists. Our study was limited to the German-speaking part of Switzerland, as it would have exceeded our resources to code the diagnostic labels and features used in three languages. Terminologies to report obstructive airway disease in medical practice will differ among languages and countries. In our proposal we focused on the aspects of obstructive airway disease that are transportable across countries. For example, triggers for asthma symptoms differ between countries, but the proposal to always report triggers as an aspect of obstructive airway disease is internationally applicable. Furthermore, we only included letters from children enrolled in the SPAC study. However, since study participation depended on participant or parental consent—not on pediatric pulmonologist consent—we do not believe that this has introduced bias.

Implication for clinical practice and research

Standardized reporting according to our proposal will overcome prior inconsistencies between physicians with a more nuanced description than the ICD-10 codes. Standardized reporting will improve communication between physicians when children change health care provider. It will also help with future observational and interventional studies because inclusion and exclusion criteria will be more accurate. With respect to research, adding descriptors to the diagnostic terms might not help to separate asthma from non-asthma patients. It also adds complexity to the description of the diagnosis. On the positive side, it will contribute to a better description of the individual asthma phenotypes and traits which

are relevant for the child and thus be valuable to study specific subgroups of children with asthma and to support personalized health care [7]. If diagnoses written in medical records are standardized, research can be done at a faster rate and at lower cost because physicians and researchers do not need to search as long for information in medical records [26, 27].

Conclusion

This study recommends standardizing reporting of obstructive airway disease in children, which includes the features that are relevant for treatment and follow-up. Implementation of these recommendations can lead to better clinical care for these children, as well as more accurate data for clinical research.

Ethics approval and consent to participate

The Bernese ethics committee (KEB 2016-02176) approved the Swiss Pediatric Airway Cohort and all participating parents and adolescents aged above 14 years gave informed consent.

Authors' contributions

CdJ, EP, CAG, MG, and CK developed the concept and designed the study. CdJ, EP, MCM, DMS, AJ, FS, CC, NR, JB, and AM collected the data. CdJ analyzed the data, with aid of EP, CAG, and MG. CdJ, EP, CAG, MG, and CK drafted the manuscript. All authors contributed to iterations and approved the final version.

Acknowledgements

We are grateful to all the children and their parents for participating in this study. Data collection was funded by the Swiss National Science Foundation (32003B_162820/1) and supported by the Research Fund of the Swiss Lung Association, Bern (2019-03_641670). Further funding to develop the Swiss Pediatric Airway Cohort (SPAC) came from the Lung League St. Gallen, Switzerland.

Availability of data and material

The SPAC dataset is available upon reasonable request by contacting Claudia Kuehni.

439 References

- 440 [1] GINA. Global strategy for asthma management and prevention.
 441 <https://ginasthma.org/wp-content/uploads/2019/04/wms-GINA-2019-report-V1.3-002.pdf>.
 442 Date last updated: 2019. Accessed December, 12th, 2019.
- 443 [2] NICE. Guideline asthma diagnosis and monitoring
 444 [https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-asthma-diagnosis-and-](https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-asthma-diagnosis-and-monitoring-pdf-4656178047)
 445 [monitoring-pdf-4656178047](https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-asthma-diagnosis-and-monitoring-pdf-4656178047). Date last updated: November 2017. Date last accessed:
 446 December, 12th, 2019.
- 447 [3] Fernandes RM, Robalo B, Calado C, Medeiros S, Saianda A, Figueira J, et al. The multiple
 448 meanings of "wheezing": a questionnaire survey in Portuguese for parents and health
 449 professionals. *BMC Pediatr.* 2011;11:112.
- 450 [4] Douros K, Everard ML. Time to Say Goodbye to Bronchiolitis, Viral Wheeze, Reactive
 451 Airways Disease, Wheeze Bronchitis and All That. *Front. Pediatr.* 2020;8:218.
- 452 [5] Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits:
 453 toward precision medicine of chronic airway diseases. *Eur Respir J.* 2016;47:410-9.
- 454 [6] McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, et al. Treatable traits:
 455 a new paradigm for 21st century management of chronic airway diseases: Treatable Traits
 456 Down Under International Workshop report. 2019;53.
- 457 [7] Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After asthma:
 458 redefining airways diseases. *Lancet.* 2018;391:350-400.
- 459 [8] Simpson AJ, Hekking PP, Shaw DE, Fleming LJ, Roberts G, Riley JH, et al. Treatable traits in
 460 the European U-BIOPRED adult asthma cohorts. *Allergy.* 2019;74:406-11.
- 461 [9] World Health Organization. ICD-10 : international statistical classification of diseases and
 462 related health problems. tenth revision, 2nd ed. 2004.
- 463 [10] Falck L, Zoller M, Rosemann T, Martinez-Gonzalez NA, Chmiel C. Toward Standardized
 464 Monitoring of Patients With Chronic Diseases in Primary Care Using Electronic Medical
 465 Records: Systematic Review. *JMIR Med Inform.* 2019;7:e10879.
- 466 [11] Loughheed MD, Minard J, Dworkin S, Juurlink MA, Temple WJ, To T, et al. Pan-Canadian
 467 REspiratory STandards INitiative for Electronic Health Records (PRESTINE): 2011 national
 468 forum proceedings. *Can Respir J.* 2012;19:117-26.
- 469 [12] van Steenkiste BC, Jacobs JE, Verheijen NM, Levelink JH, Bottema BJ. A Delphi
 470 technique as a method for selecting the content of an electronic patient record for asthma.
 471 *Int J Med Inform.* 2002;65:7-16.
- 472 [13] Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, et al.
 473 Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. *J*
 474 *All Clin Immunol Pract.* 2019;7:578-88.e2.
- 475 [14] Wi CI, Sohn S, Ali M, Krusemark E, Ryu E, Liu H, et al. Natural Language Processing for
 476 Asthma Ascertainment in Different Practice Settings. *J All Clin Immunol Pract.* 2018;6:126-
 477 31.
- 478 [15] Blake TL, Chang AB, Chatfield MD, Marchant JM, Petsky HL, McElrea MS. How does
 479 parent/self-reporting of common respiratory conditions compare with medical records
 480 among Aboriginal and Torres Strait Islander (Indigenous) children and young adults? *J*
 481 *Paediatr Child Health.* 2019.
- 482 [16] Pedersen ESL, de Jong CCM, Ardura-Garcia C, Barben J, Casaulta C, Frey U, et al. The
 483 Swiss Pediatric Airway Cohort (SPAC). *ERJ Open Res.* 2018;4.

- 484 [17] Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ*.
485 1995;311:376-80.
- 486 [18] Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk
487 of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med*.
488 2000;162:1403-6
- 489 [19] Pescatore AM, Dogaru CM, Duembgen L, Silverman M, Gaillard EA, Spycher BD, et al. A
490 simple asthma prediction tool for preschool children with wheeze or cough. *J Allergy Clin*
491 *Immunol*. 2014;133(11):111-8.
- 492 [20] Minard JP, Turcotte SE, Loughheed MD. Asthma electronic medical records in primary
493 care: an integrative review. *J Asthma*. 2010;47:895-912
- 494 [21] Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes
495 of childhood wheeze and cough: a novel approach with prognostic relevance. *Eur Respir J*.
496 2008;31:974-81
- 497 [22] Fitzpatrick AM, Bacharier LB, Guilbert TW, Jackerson DJ, Szeffler SJ, Beigelman A, et al.
498 Phenotypes of recurrent wheezing in preschool children: identification by latent class
499 analysis and utility in prediction of future exacerbation. *J Allergy Clin Immunol Pract*.
500 2019;7(3):915-924.
- 501 [23] Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are they real.
502 *Clin Exp Allergy*. 2010;40:1130-1141
- 503 [24] Spycher BD, Cochrane C, Granell R, Sterne JAC, Silverman M, Pedersen E, et al.
504 Temporal stability of multitrigger and episodic viral wheeze in early childhood. *Eur Respir J*.
505 2017;50.
- 506 [25] van Wonderen KE, Geskus RB, van Aalderen WM, Mohrs J, Bindels PJ, van der Mark LB,
507 et al. Stability and predictiveness of multiple trigger and episodic viral wheeze in
508 preschoolers. *Clin Exp Allergy*. 2016;46:837-47.
- 509 [26] Minard JP, Dostaler SM, Taite AK, Olajos-Clow JG, Sands TW, Licskai CJ, et al.
510 Development and implementation of an electronic asthma record for primary care:
511 integrating guidelines into practice. *J Asthma*. 2014;51:58-68.
- 512 [27] Barkhuysen P, de Grauw W, Akkermans R, Donkers J, Schers H, Biermans M. Is the
513 quality of data in an electronic medical record sufficient for assessing the quality of primary
514 care? *J Am Med Inform Assoc*. 2014;21:692-8.

515 **Figure and tables**

516 **Figure 1** Flow chart for inclusion of one hospital letter per child diagnosed with obstructive
517 airway disease participating in the Swiss Paediatric Airway Cohort (SPAC)

518

519 **Figure 2** Flow chart of qualitative and quantitative analysis steps, as well as the Delphi
520 process

521

522 **Figure 3** The proportion of letters in which pediatric pulmonologists reported features of
523 children with obstructive airway disease, stratified by the patients age (N=562)

524

525 **Figure 4** The proportion of letters in which pediatric pulmonologists report features of
526 children with obstructive airway disease, stratified by center (N=562)

527

528 **Table I** Characteristics of study participants (N=562)

	Total n (%)
Age	
0-4 years	112 (20)
5-9 years	211 (38)
10-17 years	239 (43)
Sex, male	365 (65)
Clinic	
A	187 (33)
B	149 (27)
C	80 (14)
D	66 (12)
E	35 (6)
F	25 (4)
G	20 (4)
First visit	226 (40)
Follow-up visit	336 (60)
Reported respiratory symptoms*	
Wheeze	388 (69)
Dyspnoea	278 (49)
Exercise related breathing problems	343 (61)
Night cough	232 (41)
Prolonged cough (> 4 weeks)	169 (30)
Medication*	
Any asthma inhaler	509 (91)
SABA alone	119 (21)
ICS +/- SABA	203 (36)
ICS + LABA	187 (33)

529 * in the last 12 months

530

531

Table II. Standardized reporting recommendations for children's obstructive airway disease based on consensus among pediatric pulmonologists through the Delphi process.

Proposed standardized reporting recommendations for obstructive airway disease in children.

- 1 **Diagnosis:** asthma or recurrent obstructive bronchitis¹
- 2 **Certainty:** confirmed (name tests, month/year) or suspected² (state differential diagnosis)
- 3 **Triggers**
- 4 **Symptom control:** well, partly, or uncontrolled³
- 5 **Risk of exacerbation:** number of severe exacerbations⁴ in the last 12 months and month/year of last severe exacerbation
- 6 **Atopy:** sensitizations and clinical relevance
- 7 **Treatment adherence:** poor, moderate or good⁵
- 8 **Symptom perception:** state symptom perception if poor perceived⁶

¹ **Diagnosis:** use obstructive bronchitis if attacks are **only** triggered by infections. Use asthma if any other trigger (such as exercise outside of an infection period or an allergic trigger) is present. Use severe asthma if the child has severe asthma or difficult to treat asthma if the child has difficult to treat asthma according to the definition from the GINA guidelines.

² **Certainty:** if the diagnostic tests were inconclusive or if the child could not perform diagnostic tests, state "suspected asthma."

³ **Symptom control:** use "well," "partly," or "uncontrolled," according to the definition from the GINA guidelines.

⁴ **Risk of exacerbation:** if an attack needed an emergency consultation, state "severe exacerbation".

⁵ **Treatment adherence:** good = almost always; moderate = only for symptoms; poor = very rarely.

⁶ **Symptom perception:** if the patient/parents report different subjective symptom control compared to symptom control from the physical examination and/or test results, use "poor symptom perception"

550 **Table III** Examples of standardized reporting of children's obstructive airway disease

Example 1: Patient aged 8 years

Diagnosis

1. Asthma

- confirmed by reversible bronchial obstruction in lung function testing (01/2018)
- triggers: sport and pollen
- symptoms: partially controlled
- no hospitalizations, last severe exacerbation in 06/2020
- atopic sensitization: grasses with clinical relevance and cats without clinical relevance
- good adherence
- poor symptom perception

2. Atopic eczema

Example 2: Patient aged 4 years

Diagnosis

1. Suspected asthma

- DD recurrent obstructive bronchitis
- triggers: respiratory infections and physical activity
- symptoms: well controlled
- 3 hospitalizations, last severe episode in 01/2021
- atopic sensitization: birch without clinical relevance
- poor adherence

2. Atopic eczema

551

552

553

Supplementary material

Table E1: Diagnostic labels and features used by paediatric pulmonologists to describe the diagnosis of obstructive airway disease: grouping of wording from the qualitative analysis, order of use, frequency, and recommendation from the Delphi process (N=562). We used the original wording from letters, which was mostly in German, but letters included a few English terms (such as “episodic viral wheeze”, or “brittle asthma”)

Diagnostic labels and features	Terms used in original letter	n (%)	Recommendation from Delphi process
Diagnostic label	Asthma, asthma bronchiale, small airway disease, episodic viral wheeze, multiple trigger wheeze, obstructive bronchitis	562 (100%)	Use obstructive bronchitis if attacks are only triggered by infections. Use asthma if any other trigger (such as exercise outside of an infection period or an allergic trigger) is present.
Certainty of diagnosis	Verdacht auf, hochgradiger Verdacht auf, Dringender Verdacht auf, Möglicherweise, Wahrscheinlich, Sehr wahrscheinlich	117 (21%)	State suspected asthma if the diagnostic tests were inconclusive or if the child could not perform diagnostic tests.
Exclusion of differential diagnosis	Schweisstest, Bronchoskopie, Röntgenthorax, CT-Thorax		
Age-related phenotype	Frühkindliches, Kleinkindes, Infantiles	49 (9%)	Age-related phenotypes should not be stated in the diagnosis list
Symptoms	Husten, Wheeze, Atemnot / ohne Atemnot, Asymptomatisch	38 (7%)	Symptoms should not be stated in the diagnosis list
Symptom perception	Subjektiv, Schlechte perception	11 (2%)	State symptom perception if the patient has poor perception. Poor symptom perception: if the patient/parents report different subjective symptom control compared to symptom control from the physical examination and/or test results.
Pattern of symptoms over time	Rezidivierende, Wiederholte, Mehrfache, Frequenz, Chronisch, Episodisch, Monatlich	135 (24%)	Patterns of symptoms over time should not be stated as separate feature in the diagnosis list. Recurrent should be stated as part of obstructive bronchitis.
Seasonal/Perennial	Saisonal, Perennial	20 (4%)	Seasonal/perennial should not be stated in the diagnosis list
Triggers	Allergisch, Exogen, Pollinosum, Nicht allergisch, Infekt, Anstrengung, Multifaktoriell, Wetter, Psychisch, Triggers/Auslöser unklar	468 (81%)	State triggers
Related measures of disease severity	Leichtes, Mildes, Nicht aktiv, Difficult to treat	99 (18%)	State the number of severe exacerbations in the last 12 months and month/year of last severe exacerbation. Severe exacerbation: if an attack needed an emergency consultation
Exacerbations	Exazerbation, Hospitalisation, Atemunterstützung, Intensivmedizin, Respiratorische, Partialinsuffizienz, Respiratorische, globalinsuffizienz		
Stability	Instabil, Stabil, Sehr stabil, Brittle		
Effect on daily life	Leistungsintoleranz, Keine Einschränkungen		
Lung function	Lungenfunktion, Obstruktiv, Leichte, Mittelschwere, Nicht obstruktiv, Gemischt	36 (6%)	Diagnostic test results other than allergy tests results should be stated in

	obstruktiv und restriktiv, FEV1		the diagnosis list to state the level of certainty of the diagnosis
Broncho-dilator Reversibility	Teilreversibilität, Vollständig, Fixiert		
Airway inflammation	FeNO	11 (2%)	Diagnostic test results other than allergy tests results should be stated in the diagnosis list to state the level of certainty of the diagnosis
Airway hyper-responsiveness	Belastungs-Lungenfunktion, Methacholine, Mannitol, Bronchiale Hyperreagibilität (Leichte, Mittelschwere, Schwere, Keine)	52 (9%)	Diagnostic test results other than allergy tests results should be stated in the diagnosis list to state the level of certainty of the diagnosis
Atopy	Sensibilisierung	431 (77%)	State sensitizations and clinical relevance
Klinischer Relevanz	Fraglicher, Gesicherter, Wenig, Eindeutig, Hochrelevant, Wahrscheinlich, Wahrscheinlich nicht, Ohne eindeutige, Keine		
Therapy	SABA (Ventolin), LABA, ICS, (Axotide Flutiform, Seretide, Symbicort) LTRA (Montelukast), Bronchovaxom, Omalizumab, Ohne Therapie	46 (8%)	Therapy should not be stated in the diagnosis list
Symptom control	Kontrolliert, Kontrolliert nach GINA, Gut kontrolliert, Vernünftig kontrolliert, Partiiell bis gut kontrolliert, Partiiell kontrolliert, Teilweise, kontrolliert, Mässig kontrolliert, Ungenügend kontrolliert, Unkontrolliert, Nicht kontrolliert, Ungenügend eingestellt, Schlecht eingestellt, Mässiger Kontrolle, Nicht genügend Kontrolle, Unzureichender, Symptomkontrolle	139 (25%)	State symptom control as well, partly, or uncontrolled, according to the definition from the GINA guideline.
Therapy response	Gut auf Therapieansprechend, Schlecht auf Therapie ansprechend, Hochsignifcant verbessert nach Therapie	3 (1%)	State treatment adherence as good = almost always, moderate = only for symptoms or poor = very rarely
Compliance	Malcompliance, Mässige compliance, Oft vergessen	3 (1%)	Compliance should not be stated in the diagnosis list
Risk of future asthma	Asthma predictive index (API), Predicting asthma risk in children (PARC) score	10 (2%)	Risk of future asthma should not be stated in the diagnosis list
Terms not grouped into features	Typ II, Atypisch, Bekanntes, Residuelles, Seit	-	-

Table E2. Delphi questionnaires to reach consensus on standardized reporting of obstructive airway disease in children

First Delphi questionnaire Recommendation	Results from the analysis	Agree	Dis- agree	Agree -ment	Second Delphi questionnaire Recommendation	Agree	Dis- agree	Agree -ment	Third Delphi questionnaire Recommendation	Agree	Dis- agree	Agree -ment
Diagnostic labels												
Obstructive bronchitis and wheeze are used interchangeably and should be grouped together as wheeze.	Both terms are mainly used in children aged 0-4 years (>88%).	1	6	14%	Below the age of 5, we should use one label "obstructive airway disease" instead of "obstructive bronchitis", "wheeze", "frühkindliches asthma" oder "infantiles asthma"	1	6	14%	Below the age of 5 years, we should distinguish two conditions A) recurrent obstructive bronchitis and B) suspected asthma (which cannot be confirmed yet, because the child cannot perform lung function testing).	7	0	100%
Asthma bronchiale and asthma are used interchangeably and should be grouped together as asthma	Both terms are used at all ages	4	3	57%	Asthma bronchiale is an old fashion term, which has been replaced with asthma in modern literature and guidelines. Therefore, the term asthma bronchiale should be stated as asthma above the age of 5 years.	6	1	86%				
Features												
Triggers should be stated	83% stated triggers in the diagnosis field of hospital letter	6	1	86%								
Severity should not be stated in diagnosis field, because it is subjective and mild/moderate are not used in guidelines anymore. Severity is partially covered by symptoms control	3% stated severity	3	4	43%	In children with severe asthma severity should be stated. Hereby it should be differentiated between: "Severe Asthma" and "difficult to treat Asthma"	6	1	86%				
Number and timepoint of last exacerbation should be stated as number of exacerbations and hospitalisations ever in life and month + year of the last exacerbation	13% stated exacerbations/hospitalisations	4	3	57%	Number and timepoint (month/year) of exacerbations should only be stated in the diagnosis list if severe (leading to hospitalisation), it was recent (within the last 12 months), and relevant for follow-up	7	0	100%				
Frequency of episodes/recurrence should not be stated in diagnosis field. It is very variable and partially covered by number of exacerbations.	<1% stated frequency of episodes/recurrence	5	2	71%					Recurrence should be stated as part of the diagnostic label "obstructive bronchitis", because it needs to be recurrent to receive the diagnosis	7	0	100%
Episodic/Recurrence should be stated	20% stated episodic or recurrent. Chronic was only stated in 2 children (<1%)	4	3	57%	The recurrence or persistence of symptoms is captured by the triggers and should not be stated in the diagnosis list.	7	0	100%				
Stability should not be stated in diagnosis field. It is subjective and partially covered by the number of exacerbations)	1% stated stability	7	0	100%								

First Delphi questionnaire					Second Delphi questionnaire				Third Delphi questionnaire			
Recommendation	Results from the analysis	Agree	Dis-agree	Agree-ment	Recommendation	Agree	Dis-agree	Agree-ment	Recommendation	Agree	Dis-agree	Agree-ment
Symptom control should be stated as well controlled, controlled, partially controlled or uncontrolled	25% stated symptom control, of which 50% stated good symptoms control and 50% stated partial or poor symptoms control	6	1	86%								
Limitations of sports and daily activities should not be stated in diagnosis field. It can be stated under anamnesis.	1% stated limitations	5	2	71%								
Therapy should not be stated in diagnosis field. Prescriptions can be found under treatment.	8% stated therapy	6	1	86%								
Treatment step according to GINA should be added to diagnosis field		1	6	14%	Treatment step according to GINA should not be added to diagnosis field.	6	1	86%				
Compliance should be stated in children >10 years if the compliance is poor	1% stated the compliance. Only poor compliance was stated.	5	2	71%								
Therapy response should not be stated in diagnosis field. It can be stated with the therapy	1% stated therapy response	7	0	100%								
Certainty of diagnosis should be stated as suspected if there is uncertainty about the diagnosis	21% stated that the diagnosis was suspected with different levels of certainty	7	0	100%	If the diagnosis is only suspected, then a differential diagnosis should be stated	6	1	86%				
Symptom perception should be stated in children >10 years if the symptom perception is poor	2% stated the symptom perception. Only poor symptom perception was stated.	3	4	43%	Poor perceiver should be stated as this is important information for follow-up	7	0	100%				
Symptoms should not be stated in diagnosis field. They can be found under anamnesis.	7% stated symptoms	5	2	71%								
Asthma predictive index (API) / predicting asthma risk in children (PARC) should not be stated in diagnosis field. It can be stated with the diagnostic tests.	2% stated asthma predictive index or	7	0	100%								
Since when the child was diagnosed should not be stated in diagnosis field. It can be stated under anamnesis, but is not very relevant for daily clinical practise.	<1% stated since when the child was diagnosed	7	0	100%								

First Delphi questionnaire					Second Delphi questionnaire				Third Delphi questionnaire			
Recommendation	Results from the analysis	Agree	Dis-agree	Agree-ment	Recommendation	Agree	Dis-agree	Agree-ment	Recommendation	Agree	Dis-agree	Agree-ment
Diagnostic test results other than allergy test results should be stated as for example reversible obstructive lungfunction or severe bronchial hyperreactivity in methacholine test	23% stated diagnostic test results other than allergy test results of which 95% abnormal test results and only 5% normal test results	4	3	57%	Obstructive lung function (fixed or reversible) should be in the diagnosis list.	3	4	43%	Diagnostic test results other than allergy tests results should be stated in the diagnosis list to state the level of certainty of the diagnosis	7	0	100%
					Airway inflammation measured by FeNO should be stated in the diagnosis list.	2	5	29%				
					Airway hyperresponsiveness measured by bronchial challenge tests should be stated in the diagnosis list as it reminds of a correct diagnosis.	6	1	86%				
Allergy test results should be stated as sensitizations for or no sensitizations for common inhalation allergens	77% stated allergy test result in the diagnosis field of the hospital letter	7	0	100%								
The clinical relevance of the allergy test results should be stated as with, without or unclear clinical relevance	27% stated the clinical relevance of the positive allergy test results	7	0	100%								

1497 patients invited for SPAC

73 refused


578 never replied

846 participated in SPAC


48 without a hospital letter and 45 without a questionnaire

191 hospital letters without obstructive airway disease
(without the words “asthma”, “wheeze”, and “obstructive
bronchitis”) in the diagnosis list

562 hospital letters with obstructive airway
disease in the diagnosis list from children
from whom we received a questionnaire



Features reported in the diagnosis list



Center 1, N=80 Center 2, N=149 Center 3, N=187 Center 4, N=20
Center 5, N=35 Center 6, N=25 Center 7, N=66

Journal Pre-proof

% of hospital letters

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Features reported in diagnosis list

